AbCellera Biologics Inc (NASDAQ:ABCL) has a beta value of 0.41 and has seen 0.96 million shares traded in the recent trading session. The company, currently valued at $816.69M, closed the recent trade at $2.77 per share which meant it lost -$0.02 on the day or -0.90% during that session. The ABCL stock price is -118.41% off its 52-week high price of $6.05 and 15.52% above the 52-week low of $2.34. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.58 million shares traded. The 3-month trading volume is 2.22 million shares.
The consensus among analysts is that AbCellera Biologics Inc (ABCL) is Buy stock at the moment, with a recommendation rating of 1.22. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 9 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Sporting -0.90% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ABCL stock price touched $2.77 or saw a rise of 9.18%. Year-to-date, AbCellera Biologics Inc shares have moved -51.58%, while the 5-day performance has seen it change -4.98%. Over the past 30 days, the shares of AbCellera Biologics Inc (NASDAQ:ABCL) have changed 4.34%. Short interest in the company has seen 16.25 million shares shorted with days to cover at 6.35.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 44.6% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is -80.51% off the targeted high while a plunge would see the stock gain -80.51% from the levels at last check today.
AbCellera Biologics Inc (ABCL) estimates and forecasts
Figures show that AbCellera Biologics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -5.95% over the past 6 months, with this year growth rate of -15.69%, compared to 17.30% for the industry.
ABCL Dividends
AbCellera Biologics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
Insiders own 27.93% of the company shares, while shares held by institutions stand at 39.78% with a share float percentage of 55.20%. Investors are also buoyed by the number of investors in a company, with AbCellera Biologics Inc having a total of 203.0 institutions that hold shares in the company. The top two institutional holders are BAKER BROS. ADVISORS LP with over 27.53 million shares worth more than $81.48 million. As of 2024-06-30, BAKER BROS. ADVISORS LP held 9.4033% of shares outstanding.
The other major institutional holder is BAILLIE GIFFORD & CO, with the holding of over 21.91 million shares as of 2024-06-30. The firm’s total holdings are worth over $64.86 million and represent 7.4852% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Biotechnology ETF and Vanguard Valley Forge Fds-Baillie Gifford Global Pos Impact Stock Fd. As of Oct 31, 2024, the former fund manager holds about 0.49% shares in the company for having 1.46 shares of worth $4.05 million while later fund manager owns 454.44 shares of worth $1.26 million as of Sep 30, 2024, which makes it owner of about 0.15% of company’s outstanding stock.
